Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers
- 1 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Immunologic Research
- Vol. 67 (6), 505-516
- https://doi.org/10.1007/s12026-019-09113-8
Abstract
It is believed that pathways of the immune system are responsible for eradicating cancer cells; however, their over-activation and also their ectopic expression in tumor cells and microenvironment are major contributors to tumor growth and chemoresistance. Toll-like receptor 4 (TLR4) pathway is an innate immune-related pathway which is usually overexpressed in tumor cells that leads to excessive pro-inflammatory cytokines and eventually results in tumor survival, drug resistance, and metastasis. In this study, we investigated whether TLR4 expression is affected upon the treatment of breast and ovarian cancer cells with common chemotherapeutics (paclitaxel, cisplatin, doxorubicin, and arsenic trioxide) and if TLR4 inhibition using its specific inhibitor TAK-242 could enhance cancer cells’ response to the drugs. Both breast (MCF7) and ovarian (2008C13) cancer cells experienced an elevated expression of TLR4 after treatment with the drugs. The expression of this receptor was also upregulated in cisplatin-resistant 2008C13 cells; however, it was significantly higher upon short-term treatment with cisplatin. More importantly, the combination treatment of the drugs with TAK-242 intensified the chemosensitivity of six different breast and ovarian cancer cells to chemotherapeutic drugs. It was also identified that co-treatment of paclitaxel and TAK-242 not only led to enhanced G2/M arrest and apoptosis but also satisfactorily decreased the expression of TLR4 and different interleukins in these cells. Taken together, the results of the present study emphasize that chemotherapy may lead to chemoresistance through inducing TLR4 expression, and therefore inhibiting this receptor using TAK-242 could be a promising approach to improve the outcome of chemotherapy in foreseeable future.Keywords
Funding Information
- Research reported in this publication was supported by a grant from Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. (1)
This publication has 51 references indexed in Scilit:
- Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancersOncoTargets and Therapy, 2013
- Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS productionCell Death & Disease, 2013
- Toll-Like Receptor 4 Inhibitor TAK-242 Attenuates Acute Kidney Injury in Endotoxemic SheepAnesthesiology, 2011
- Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinomaWorld Journal of Gastroenterology, 2011
- Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasisBMC Cancer, 2010
- Interleukin-6 in bone metastasis and cancer progressionEuropean Journal of Cancer, 2010
- TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancerOncogene, 2009
- Paclitaxel Binding to Human and Murine MD-2Online Journal of Public Health Informatics, 2008
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapyImmunological Reviews, 2007
- Inflammation and Cancer: A Double-Edged SwordCancer Cell, 2007